<DOC>
	<DOCNO>NCT00005931</DOCNO>
	<brief_summary>The purpose study test effectiveness SU5416 patient AIDS-related Kaposi 's sarcoma ( KS ) .</brief_summary>
	<brief_title>SU5416 Patients With AIDS-Related Kaposi 's Sarcoma Who Have Not Responded Treatment</brief_title>
	<detailed_description>Patients give SU5416 via twice-weekly intravenous infusion 4-week treatment cycle . Any patient experience unacceptable toxicity deem respond study drug ( evidence disease progression ) permit continue receive SU5416 4-week treatment cycle ( maximum 1 year therapy ) patient experience either unacceptable toxicity tumor progression , define protocol .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Semaxinib</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are least 18 year old . Have KS . Have take paclitaxel , DaunoXome , Doxil KS either get good could tolerate treatment therapy . Have 1 follow symptom KS : 5 lesion ( sore ) , generalize KSrelated edema ( swell ) without sore , KSrelated edema arm leg . Agree use effective method birth control study . Exclusion Criteria Patients eligible study : Are pregnant breastfeeding . Are allergic Cremophor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2000</verification_date>
	<keyword>Skin Neoplasms</keyword>
	<keyword>Sarcoma , Kaposi</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Enzyme Inhibitors</keyword>
	<keyword>SU 5416</keyword>
	<keyword>Protein-Tyrosine Kinase</keyword>
</DOC>